Cybin

Toronto, Canada Founded: 2002 • Age: 24 yrs Listed
Psychedelic therapeutics for psychiatric disorders are developed and provided.

About Cybin

Cybin is a publicly listed company based in Toronto (Canada) founded in 2002 by Eric So. Psychedelic therapeutics for psychiatric disorders are developed and provided. It operates on a HealthTech model. The company has 50 employees. Cybin has completed 2 acquisitions, including Adelia Therapeutics and Small Pharma. Its website cybin.com draws about 47 thousand monthly visits. Cybin offers products and services including CYB003, CYB004, and CYB005. Its focus areas include Biotechnology and Neuropsychiatry. Its legal entity is Cybin Corp.

Company details

Cybin is engaged in the development of novel neuropsychiatry therapies aimed at transforming mental health treatment. The company is involved in creating proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches. Therapies such as CYB003 for Major Depressive Disorder, CYB004 for Generalized Anxiety Disorder, and CYB005 for CNS disorders are being developed. Partnerships with world-renowned pioneers and a focus on tryptamine-based therapies are maintained to address unmet needs in mental health. The sector of operation includes biotechnology with a specific emphasis on neuropsychiatry solutions.

  • Headquarters Toronto, Canada
  • Employees 50
  • Founders Eric So
  • Stage Public
  • Sectors
    Healthcare
  • Website category Finance · Investing
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website cybin.com
  • Social LinkedIn X Facebook Instagram
  • Legal Name Cybin, Inc.
Operational Areas
Key Metrics
  • Net Profit
    -$146.79 M (USD)
    -80.8
    as on Mar 31, 2026
  • EBITDA
    -$141.3 M (USD)
    -38.01
    as on Mar 31, 2026
  • Latest Funding Round
    $50M (USD), Post-IPO

    Jun 2025

  • Investors
  • Employee Count
    50
  • Investments & Acquisitions

Products & Services of Cybin

Cybin offers a comprehensive portfolio of products and services, including CYB003, CYB004, and CYB005.

CYB003
Neuropsychiatry Therapy

Therapy developed for Major Depressive Disorder treatment.

CYB004
Neuropsychiatry Therapy

Therapy designed for Generalized Anxiety Disorder treatment.

CYB005
Neuropsychiatry Therapy

Therapy targeting CNS disorders under active development.

Funding Insights of Cybin

  • Total Rounds 7
  • Last Round Post-IPO β€” $50M
  • First Round $477,437

    (May 2020)

  • Investors Count 2

All 7 funding rounds of Cybin with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2025$50MPost-IPO––
Mar 2024$150MPost-IPO––
Mar 2022$317,098Post-IPO––
–
Feb 2021Post-IPO––
–
Oct 2020$27.35MPost-IPO––
–
Jun 2020$1.54MPost-IPO––
–
May 2020$477,437Post-IPO––
–
Valuation history

2 investors in total: 2 institutional.

Investors in Cybin

Cybin has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Deep Track Capital and High Trail Capital.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Deep Track Capital is engaged in biotechnology investment activities.
deeptrackcapital.comGreenwich, United States
High Trail Capital is engaged in investment management services.
2019hightrailcapital.com
Premium access

Investor details for Cybin

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Cybin

54 people are tracked at Cybin (32 in leadership, 10 in board & advisors, 12 in team); the tracked headcount is 50.

NameRoleGroup
Eric So
Co-FounderLeadership
Aaron Bartlone
COOLeadership
Sarah Hamilton
Director Financial Operations & Strategic OperationsLeadership
Peng Chen
Associate DirectorLeadership
Greg Cavers
CFOLeadership
Alex Nivorozhkin
Chief Scientific OfficerLeadership
Geoff Varty
Head, R&DLeadership
Pradip Pathare
Senior Director, Process ChemistryLeadership
Lori Challenger
Chief Compliance, Ethics & Administrative OfficerLeadership
Gabe F.
Chief Legal OfficerLeadership
Kristen Irizarry
Executive Assistant To Chief Executive OfficerLeadership
Ryan Richardson
Director, Information TechnologyLeadership
Liz Galic
Director, OperationsLeadership
Erica Olson
VP, Corporate ControllerLeadership
Kathy Dorsey
Senior Director Clinical OperationsLeadership
Meghan Good
Associate DirectorLeadership
Marcelo Gutierrez
Vp, Head Of Clinical PharmacologyLeadership
Dnb Amir Inamdar Mbbs Mfpm (Psych)
Chief Medical OfficerLeadership
Amir Inamdar
Chief Medical OfficerLeadership
Emma Hodge
Head Of Legal EuropeLeadership

34 more people are available in the full profile.

Premium access

Complete people profiles for Cybin

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Cybin

Cybin is a publicly listed company on the NEO with ticker symbol CYBN in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date10 Nov 2020
  • Listed onNEO: CYBN
  • Listed entityCybin, Inc.
  • Exchange sectorHealth technology
  • ISINCA4234921076
  • Share price11.58 CAD (+4.23% on the day) · 2026-01-05
  • Market capitalisation577,773,678.00 CAD
  • EPS (diluted, trailing year)-5.43 CAD
  • Volume (last session)3,715
  • Analyst consensusStrong buy

Financials of Cybin

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025-204.6M CAD-196.9M CAD
2024-113.1M CAD-142.7M CAD
2023-78.1M CAD-78.4M CAD
2022-47.5M CAD-51.3M CAD
2021-67.6M CAD-63.7M CAD
Premium access

Detailed financial statements for Cybin

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Cybin

Cybin has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Adelia Therapeutics and Small Pharma.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Psychedelic-based therapeutics for mental health conditions are developed.
smallpharma.comLondon, United Kingdom2015Aug 2023β€’β€’β€’β€’
Proprietary psychedelics-based therapeutics for neurodegenerative diseases are developed.
adeliatx.comFitchburg, United States2020Dec 2020β€’β€’β€’β€’
Premium access

Complete acquisition details for Cybin

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Cybin

6 dated milestones of Cybin across 23 years, from founding to its latest funding, stage changes and deals.

  1. Founded Cybin is founded.
  2. Funding First funding round of $477K.
  3. IPO Lists on the stock exchange (IPO).
  4. Acquisition Acquires Adelia Therapeutics.
  5. Acquisition Acquires Small Pharma.
  6. Funding Latest funding round, Post-IPO, of $50.0M.

Web traffic of Cybin

The website of Cybin (cybin.com) receives about 47.3K visits a month and ranks #655,046 among all websites worldwide, #6,440 in Investing.

  • Monthly visits
    47.3K

    ▼ 17.7% vs previous month

  • Unique visitors
    37.8K

    per month

  • Global rank
    #655,046

    among all websites

  • Category rank
    #6,440

    Finance · Investing

Similar websites

Websites whose visitors overlap most with Cybin. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
greenmarketreport.com
89%
View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Cybin

Premium access

Complete news archive for Cybin

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cybin

Cybin was founded in 2002 and raised its 1st funding round 18 years after it was founded.

Cybin is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.

Cybin has 50 employees.

Cybin is engaged in the development of novel neuropsychiatry therapies aimed at transforming mental health treatment. The company is involved in creating proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches. Therapies such as CYB003 for Major Depressive Disorder, CYB004 for Generalized Anxiety Disorder, and CYB005 for CNS disorders are being developed. Partnerships with world-renowned pioneers and a focus on tryptamine-based therapies are maintained to address unmet needs in mental health. The sector of operation includes biotechnology with a specific emphasis on neuropsychiatry solutions.

Cybin offers CYB003, CYB004, and CYB005.

Yes, Cybin is publicly traded on NEO under the ticker symbol CYBN.

Cybin has made 2 acquisitions, including Adelia Therapeutics, and Small Pharma.

Cybin has 2 investors. Key investors include Deep Track Capital, and High Trail Capital.

Cybin operates through Cybin Corp..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available